Peri- and intratumoral T and B lymphocytic infiltration in breast cancer

Purpose: To investigate peritumoral and intratumoral infiltrates in surgical specimens obtained from patients with invasive breast cancer, and of relating these to tumor size. Methods: Twenty-six surgical specimens obtained from patients diagnosed with breast cancer underwent immunohistochemical preparation and CD3, CD8, CD20 and CD68 labeling. The positive cells were counted in the tissue samples and correlated with the tumor size determined by imaging methods (TIA <= 2 or TIB > 2 cm). Results: There was a significant reduction in intratumoral B lymphocytes (CD20+), although this reduction could only be observed in TIA. In relation to peritumoral T lymphocytes (CD3+), there was a significant reduction in TIB, in comparison with TIA. Periturnoral and intratumoral CD3+ and CD68+ presence in completely opposite ways in both sizes of tumors. Conclusion: Periturnoral and intratumoral infiltrates of T and B lymphocytes are different and depend on tumor size.

Infiltration cells; Lymphocytes; Macrophages; Neoplasia; Immunohistochemistry

[1] Schöndorf T., Engel H., Lindemann C., Kolhagen H., Rücker A.A., Mallmann P.: “Cellular characteristics of peripheral blood lymphocytes and tumour-infiltrating lymphocytes in patients with gynaecological tumours”. Cancer Immunol Immunother., 1997, 44, 88.

[2] Murta E.F.C., Andrade J.M., Falcão R.P., Biguetti S.: “Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy”. Tumori, 2000, 86, 403.

[3] Menard S., Tomasic G., Casalini P., Balsari A., Pilotti S., Cascinelli N. et al.: “Lymphoid infiltration as a prognostic variable for earlyonset breast carcinomas”. Clin. Cancer Res., 1997, 3, 817.

[4] Mendonça M.A.O., Cunha F.Q., Murta E.F.C., Tavares-Murta B.M.: “Failure of neutrophil chemotactic function in breast cancer patients treated with chemotherapy”. Cancer Chemother. Pharmacol., 2006, 57, 663.

[5] Whiteside T.L., Parmiani G.: “Tumor infiltrating lymphocytes: their phenotype, function and clinical use”. Cancer Immunol. Immunother., 1994, 39, 15.

[6] Vgenopoulou V., Lazaris A.C., Markopoulous C., Boltetsou E., Kyriakou V., Kavantzas N. et al.: “Immunohistochemical evaluation of immune response in invasive ductal breast cancer of nototherwise-specified type”. Breast, 2003, 12, 172.

[7] Underwood J.C.E.: “Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review”. Br. J. Cancer, 1974, 30, 538.

[8] Ögmundsdóttir H.M., Pétursdóttir I., Gudmundsdóttir I.: “Interactions between the immune system and breast cancer”. Acta Oncol., 1995, 34, 647.

[9] O’Sullivan C., Lewis C.E.: “Tumor-associated leucocytes: friends or foes in breast carcinoma?”. J. Pathol., 1994, 172, 229.

[10] Stewart T., Heppner G.H.: “Immunological enhancement of breast cancer”. Parasitology, 1997, 115, 141.

[11] Stewart T.H.M., Tsai S.C.J.: “The possible role of stromal cell stimulation in worsening the prognosis of a subset of patients with breast cancer”. Clin. Exp. Metastasis, 1993, 11, 295.

[12] UICC: “TNM classification of malignant tumors”. 5th edition, New York: L. H. Sobin, C. Wittekind Wiley & Sons Inc., 1997.

[13] American Joint Committee on Cancer. Breast. In: Fleming I.D., Cooper J.S., Henson D.E., Hutter R.V.P., Kennedy B.J., Murphy G.P. et al. (eds.). AJCC Staging Manual. 5th edition, Philadelphia: Lippincott-Raven, 1997, 171.

[14] Georgiannos S.N., Renaut A., Goode A.W., Sheaff M.: “The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators”. Surgery, 2003, 134, 827.

[15] Campbell M.J., Scott J., Maecker H.T., Park J.W., Esserman L.J.: “Immune dysfunction and micrometastases in women with breast cancer”. Breast Cancer Res. Treat., 2005, 91, 163.

[16] Caras I., Grigorescu A., Stavaru C., Radu D.L., Mogos I., Szegli G., Salageanu A.: “Evidence for immune defects in breast and lung cancer patients”. Cancer Immunol. Immunother., 2004, 53, 1146.

[17] Lyange U.K., Moore T.T., Joo H.G., Tanaka Y., Herrmann V., Doherty G. et al.: “Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinomas”. J. Immunol., 2002, 169, 2756.

[18] Wolf A.M., Wold D., Steurer M, Gastl G., Gunsilius E., Grubeck-Loebenstein B.: “Increase of regulatory T cells in the peripheral blood of cancer patients”. Clin. Cancer Res., 2003, 9, 606.

[19] Nzula S., Going J.J., Stott D.I.: “Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas”. Cancer Res., 2003, 63, 3275.

[20] Coronella J.A., Spier C., Welch M., Trevor K.T.: “Antigen-driven oligoclonal expansion of tumor infiltrating B cells in infiltrating ductal carcinoma of the breast”. J. Immunol., 2002, 169, 1829.

[21] Kotlan B., Gruel N., Zafrani B., Füredi G.: “Immunoglobulin variable regions usage by B-lymphocyte infiltrating a human breast medullary carcinoma”. Immunol. Letter, 1999, 65, 143.

[22] Marrogi A.J., Munshi A., Merogi A.J., Ohadike Y., El-Habashi A., Marrogi O.L. et al.: “Study of tumor infiltrating lymphocytes and transforming growth factor-β as prognostic factors in breast carcinoma”. Int. J. Cancer, 1997, 74, 492.

[23] Katano M., Kubota E., Nagumo F., Matsuo T., Hisatsugu T., Tadano J.: “Inhibition of tumour cell growth by a human B cell line”. Biotherapy, 1994, 8, 1.

[24] Ben-Hur H., Cohen O., Schneider D., Gurevich P., Halperin R., Bala U. et al.: “The role of lymphocytes and macrophages in human breast tumorigenesis: an immunohistochemical and morphometric study”. Anticancer Res., 2002, 22, 1231.

[25] Harmey J.H., Dimitriadis E., Kay E., Redmond H.P., Bouchier-Hayes D.: “Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1”. Ann. Surg. Oncol., 1998, 5, 271.

[26] Toomey D., Harmey J., Condron C., Kay E., Bouchier-Hayes D.: “Phenotyping of immune cell infiltrates in breast and colorectal tumors”. Immunol. Invest., 1999, 28, 29.

[27] Saio M., Radoja S., Marino M., Frey A.B.: “Tumor-infiltrating macrophages induce apoptosis in activated CD8+ T cells by a mechanism requiring cell contact and mediated by both the cellassociated form of TNF and nitric oxide”. J. Immunol., 2001, 167, 5583.

[28] Leek R.D., Lewis C.E., Harris A.L.: “The role of macrophages in tumor angiogenesis”. In: Bicknell R, Lewis CE, Ferrara N.: Tumor Angiogenesis. Oxford: Oxford University Press, 1997.

[29] Leek R.D., Landers R.J., Harris A.L., Lewis C.E.: “Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast”. Br. J. Cancer, 1999, 79, 991.

[30] Valkovic T., Dobrila F., Melato M., Sasso F., Rizzardi C., Jonjic N.: “Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive breast cancer”. Virchows Arch., 2002, 440, 583.

[31] Leek R.D., Lewis C.E., Whitehouse R., Greenall M., Clarke J., Harris A.L.: “Association of macrophage infiltration with angiogenesis and invasive breast cancer”. Cancer Res., 1996, 56, 4625.